Two years without progression in an ovarian cancer trial

After two years of treatment, Nora was told it was time to stop.

The nodules in her lungs were still stable. The largest measured about seven millimeters, and there was no clear sign of progression. But the amount of protein in her urine had risen enough that she needed to stop taking surufatinib. Toripalimab, the other drug in the combination, had reached the end of its planned two-year course.

For a moment, she did not know what to say. She had grown used to taking tablets every day and returning to the hospital for infusions and tests. She had wanted a break from treatment. Now that it was possible, she worried about losing the control it had given her.

Two years earlier, her concerns had been more immediate. The cancer had returned, and when the doctors raised chemotherapy again, she asked to discuss something else.

Nora had been 53 at her first diagnosis. Before she became ill, she worked in administration at a small company. She liked getting arrangements settled. If something fell through, she found the right person, changed the appointment and sorted it out. Unfinished business bothered her.

After she noticed an abdominal lump, scans suggested a malignant tumor in her right ovary. Tumor markers in her blood were also markedly raised. She underwent surgery to remove the uterus, both ovaries and fallopian tubes, and the omentum, a fold of fatty tissue in the abdomen, as part of the staging procedure.

Pathology confirmed stage IC ovarian clear cell carcinoma.

She understood that it was an early-stage cancer. She also understood that surgery would be followed by chemotherapy. She wanted to finish the treatment and return to the life she knew.

After the first cycle, however, she developed a severe bowel obstruction caused by adhesions from surgery. Another operation was needed, this time with an ileostomy: an opening through the abdominal wall that temporarily allowed bowel contents to drain into a bag.

At first, she concentrated on learning to look after the stoma. Then she began working out how to dress, what to take when she left home and where she could deal with the bag if she needed to. Ordinary outings required preparation she had never had to consider.

Visitors urged her to forget work and concentrate on recovery. She knew they were trying to help. Still, answering a call from a colleague or finding an old document gave her something else to think about for a while.

She completed six cycles of carboplatin and paclitaxel. About eight months after finishing chemotherapy, following a further period of recovery, she had surgery to reverse the ileostomy.

The stoma was gone, but the experience stayed with her. She was more watchful about eating and any discomfort in her abdomen. When someone told her that an unpleasant part of treatment would soon be over, she remembered how one complication had altered months of her life.

About 14 months after her initial diagnosis, she developed chest pain. Tests found bone destruction and a mass in the lower part of her sternum. The lesion was removed, and pathology confirmed recurrent ovarian clear cell carcinoma.

She found it hard to connect the pain in her chest with the cancer that had been removed from her abdomen. Now she needed to know what would follow this operation, and feared the answer.

The recurrence had been found about 9.8 months after her last platinum-based chemotherapy. That interval placed her in the platinum-sensitive category, making further platinum-based chemotherapy a standard option worth considering.

She did not want it.

The earlier bowel obstruction had been caused by postoperative adhesions. But in her memory, the operations, chemotherapy, stoma care and long recovery were bound together. She could not discuss another course of treatment without thinking of all of them.

“I still want treatment,” she said. “I just want to know whether there's another way.”

She needed the doctors to hear both parts.

At around 18 months from diagnosis, follow-up scans showed increasingly conspicuous nodules in both lungs. Their appearance over successive scans raised concern for metastases. Unlike the sternum lesion, which had been confirmed by pathology, the suspected lung metastases were assessed mainly through imaging.

With those changes, the question of further systemic treatment became more pressing.

During discussions with the team at Fudan University Shanghai Cancer Center, Nora learned about a phase II clinical trial for recurrent ovarian clear cell carcinoma. It combined daily oral surufatinib with an intravenous infusion of toripalimab every three weeks.

Surufatinib acts on processes that include the development of tumor blood vessels; toripalimab is an immunotherapy drug. The researchers were investigating whether the combination could help control this type of cancer.

It was an experimental treatment, with no assurance that it would work for her.

Nora asked how often she would need to come to the hospital, how the doctors would judge its effect and which symptoms she should report. Having declined chemotherapy, she did not want to rush into another treatment before understanding it.

The trial would bring its own adverse effects and regular monitoring. After discussing what it involved and signing informed consent, she enrolled.

The first month did not provide the reassurance she had hoped for. The initial scan assessment did not establish disease progression, but it did not show enough improvement to qualify as a partial response either. After the first cycle, she also coughed up a small amount of blood.

With nodules already under observation in her lungs, the sight worried her. The bleeding was mild and resolved on its own, without additional intervention. Treatment continued.

At about three months, scans showed that the lung lesions being measured had shrunk enough for a partial response.

The word “partial” mattered. The lesions were still there, and she still needed treatment. But after the recurrence and the changes in her lungs, there was measurable improvement.

When her family asked, she told them the drugs appeared to be working. She would continue and see what the next tests showed.

A routine took shape: tablets each day, infusions at the scheduled intervals, regular scans and laboratory tests. Sometimes a conversation with a colleague went on long enough that she forgot she was waiting for her next assessment. At dinner, she could discuss how something tasted without immediately thinking about whether her body would tolerate it.

Around five months into treatment, testing found mild proteinuria, or protein in the urine. She had not felt noticeably unwell. Treatment continued with close monitoring, and she learned that follow-up tests also had to look for harm that she might not feel.

The cancer remained controlled through the following months, then past the one-year mark. She became familiar with the word “stable.” She still worried before scans, but reassuring results let her make plans between them.

At two years, the lung nodules had not clearly progressed. The doctors recorded 24 months of progression-free survival.

Her urine protein, however, had reached 1,919 milligrams over 24 hours, classified as grade 2 proteinuria. Surufatinib was stopped because of it. Toripalimab was also stopped after the planned two-year course.

Nora asked several times how she would be monitored afterward. She had wanted to stop taking medication every day, yet found it unsettling to give up the routine that had accompanied two years of disease control.

About two months later, the protein in her urine had decreased. She had started no new systemic cancer treatment, and there was still no evidence of progression.

The result helped her relax a little. Her lung nodules still needed watching, and future scans would still matter. But she no longer felt she had to wait for every uncertainty to be resolved before doing something for herself.

Her family noticed that she was taking an interest in household decisions again: where something should go, what to cook, who was finally going to deal with a job that had been left unfinished. She had opinions, and she was quite willing to argue for them.